Baker & McKenzie LLP
04/24/2026 | Press release | Distributed by Public on 04/24/2026 09:02
Baker McKenzie legal advisor to the banks in Egetis’ directed new share issue of SEK 350 million
Egetis Therapeutics AB (publ) has carried out a directed new share issue of shares of approximately SEK 350 million where the subscription price was set through an accelerated bookbuilding procedure.
Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment. Egetis Therapeutics is listed on the Nasdaq Stockholm main market (Nasdaq Stockholm: EGTX).
Stifel acted as Sole Global Coordinator and, together with Van Lanschot Kempen and DNB Carnegie, as Joint Bookrunners. Baker McKenzie acted as legal advisor to the Joint Bookrunners with an international capital markets team consisting of Henric Roth, Johanna Flink and Thea Hansson in Stockholm as well as Adam Farlow in London.
Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment. Egetis Therapeutics is listed on the Nasdaq Stockholm main market (Nasdaq Stockholm: EGTX).
Stifel acted as Sole Global Coordinator and, together with Van Lanschot Kempen and DNB Carnegie, as Joint Bookrunners. Baker McKenzie acted as legal advisor to the Joint Bookrunners with an international capital markets team consisting of Henric Roth, Johanna Flink and Thea Hansson in Stockholm as well as Adam Farlow in London.
Baker & McKenzie LLP published this content on April 24, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 24, 2026 at 15:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]